Below are the most recent publications written about "Boronic Acids" by people in Profiles.
-
Tang R, Wang M, Ray M, Jiang Y, Jiang Z, Xu Q, Rotello VM. Active Targeting of the Nucleus Using Nonpeptidic Boronate Tags. J Am Chem Soc. 2017 06 28; 139(25):8547-8551.
-
Al-Khalili L, de Castro Barbosa T, Ostling J, Massart J, Cuesta PG, Osler ME, Katayama M, Nyström AC, Oscarsson J, Zierath JR. Proteasome inhibition in skeletal muscle cells unmasks metabolic derangements in type 2 diabetes. Am J Physiol Cell Physiol. 2014 Nov 01; 307(9):C774-87.
-
Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. PLoS One. 2014; 9(3):e89064.
-
Poplawski SE, Lai JH, Li Y, Jin Z, Liu Y, Wu W, Wu Y, Zhou Y, Sudmeier JL, Sanford DG, Bachovchin WW. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 09; 56(9):3467-77.
-
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun 06; 121(23):4753-7.
-
Velentzas PD, Velentzas AD, Mpakou VE, Antonelou MH, Margaritis LH, Papassideri IS, Stravopodis DJ. Detrimental effects of proteasome inhibition activity in Drosophila melanogaster: implication of ER stress, autophagy, and apoptosis. Cell Biol Toxicol. 2013 Feb; 29(1):13-37.
-
Roy R, Evens AM, Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN. Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation. Leuk Lymphoma. 2013 Mar; 54(3):497-502.
-
Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012 Aug 23; 120(8):1597-600.
-
Piperdi B, Walsh WV, Bradley K, Zhou Z, Bathini V, Hanrahan-Boshes M, Hutchinson L, Perez-Soler R. Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2012 Jun; 7(6):1032-40.
-
Khan TM, Benaich N, Malone CF, Bernardos RL, Russell AR, Downes GB, Barresi MJ, Hutson LD. Vincristine and bortezomib cause axon outgrowth and behavioral defects in larval zebrafish. J Peripher Nerv Syst. 2012 Mar; 17(1):76-89.